secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2026-08-11T20:05:48+00:00
Accession:  0001193125-26-344594
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Taysha Q2 2026 net loss $46.6M; TSHA-102 pivotal dosing complete, $230M raised
------------------------------------------------------------------------------

- Net loss $46.6M ($0.13/share) vs $26.9M ($0.09) in Q2 2025; R&D expenses $38.6M vs $20.1M.
- Completed dosing in REVEAL pivotal (N=17) and ASPIRE (N=4) trials for TSHA-102 in Rett syndrome; topline interim data expected 1H 2027.
- TSHA-102 generally well tolerated with no severe treatment-related SAEs or DLTs across 33 patients as of Aug 2026 cutoff.
- Completed $230M follow-on offering; cash and equivalents $455.4M as of June 30, 2026, runway into 2H 2028.
- Expanded Catalent partnership for commercial manufacturing; appointed Mike Johannesen as Chief Legal Officer in June 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312526344594/0001193125-26-344594-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312526344594/d161230d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-344594

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer